EVERSAN and Havas Health & You announced an exclusive strategic partnership agreement, inclusive of data, analytics and predictive platforms, combined with commercialization services, to offer to health and wellness clients worldwide.
The United States plans a massive testing effort involving more than 100,000 volunteers and a half dozen or so of the most promising vaccine candidates in an effort to deliver a safe and effective one by the end of 2020, scientists leading the program told Reuters.
With a busy week for biotech quarterly and annual reports, here is a look at some of the top stories.
Fingerpaint announced a new partnership with Thrive Global aimed at educating employees through personal health and wellness content and empowering them with the tools they need to improve productivity and manage stress.
The U.S. FDA denied Lexicon Pharmaceuticals Inc.’s appeal against the rejection of the add-on treatment Zynquista for type 1 diabetes, marking the company’s third major setback during 2019.
Parexel will tap into real-world data to connect the biopharmaceutical services provider to data from the company’s clinical trials through a multi-year partnership with Bay Area-based Datavant.
The American College of Surgeons and Harvard Business School’s Institute for Strategy and Competitiveness announced a new partnership aimed at improving health care value.
BW Health Group announces a strategic partnership with Occam Health Services and the appointment of Scotty Bowman as president of Occam.
Abbott announced the next phase of partnership with the U.S. Department of Defense and researchers from the Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) Network, one of the largest traumatic brain injury efforts of its kind.
The U.S. Food and Drug Administration approved Sanofi’s new pediatric vaccine immunizing children against six diseases.